Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




FDA Clears New Blood Test to Aid in Diagnosis of Mastocytosis

By LabMedica International staff writers
Posted on 30 May 2012
The US Food and Drug Administration (FDA; Silver Spring, MD, USA) has now approved the use of a tryptase assay to provide a more specific diagnostic tool to physicians suspecting cases of systemic mastocytosis. More...
The assay is also pending approval for use in diagnosing systemic anaphylaxis.

Mastocytosis, the group of rare chronic disorders found in children and adults, is caused by an excess of mast cells, cells normally vital to the inflammatory process and may play protective roles in wound healing and fighting infections. An abnormal burden of the chemicals released from too many of these cells can cause several symptoms ranging in intensity from mild to severe. The symptoms of mastocytosis are often similar to an allergic reaction; however, mastocytosis may occur spontaneously rather than be triggered by an allergen.

The newly approved test, ImmunoCAP Tryptase, measures the level of tryptase in the blood and provides a biochemical indicator on the basis that a persistently elevated baseline level of tryptase is known to be an indication of possible mastocytosis.

The assay was developed by the laboratory led by mast cell expert Lawrence Schwartz, MD, PhD, at Virginia Commonwealth University (VCU; Richmond, VA, USA). Dr. Schwartz, chair of the Division of Rheumatology, Allergy and Immunology and the Charles and Evelyn Thomas, professor of Medicine at VCU, noted, “A physician cannot diagnose systematic mastocytosis based only on a physical examination. The FDA approval of the tryptase assay will provide doctors with an additional diagnostic tool.”

VCU first licensed the tryptase assay in 1993 to Pharmacia, now named Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The assay is being further reviewed by the FDA for additional potential applications, including diagnosis of systemic anaphylaxis, prediction of increased risk for future episodes of severe anaphylaxis, and use by medical examiners to evaluate cause of death. “When somebody dies without a clear cause, by measuring postmortem tryptase levels, an increased level of tryptase provides support for an anaphylactic event near the time of death,” said Dr. Schwartz.

Related Links:

Virginia Commonwealth University
Thermo Fisher Scientific, Inc.
US Food and Drug Administration



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.